ArticleClinical and translational radiation oncology2026
Pre-PROTO-PRIME: stereotactic body proton therapy to the prostate and pelvic nodes for high-risk and node-positive prostate cancer - feasibility, acute toxicity and dosimetric insights.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to assess the clinical feasibility, acute toxicity, and dosimetric advantages of stereotactic body proton therapy (SBPT) to the prostate and pelvic lymph nodes in high-risk and node-positive prostate cancer. Methods: This multicentric analysis included 26 patients treated from February 2024 to February 2025 with SBPT to the prostate and pelvis delivered in five fractions. The doses prescribed were 36.25 CGE to the prostate, 35 CGE to the gross nodes and 25 CGE to the pelvic nodal CTV. Acute genitourinary (GU) and gastrointestinal (GI) toxicities were evaluated up to three months post-treatment using CTCAE v5.0 criteria. Dosimetric parameters of SBPT plans were compared with matched photon-based SBRT plans, generated using identical datasets. Statistical analyses were performed using SPSS (IBM v30) and Python (v3.10). Results: No grade 3 toxicities were observed. Grade 2 GU toxicity occurred in 27 % of patients, predominantly characterized by dysuria and urinary frequency. Grade 2 GI toxicity was observed in 3.8 % of patients. SBPT demonstrated comparable target coverage to SBRT, both for the prostate (median D97%: 98.4 % vs 98.8 %) and the nodal CTV (median D97%: 97.9 % vs 98.9 %), while significantly improving sparing of organs-at-risk (OAR), notably the bowel bag (median V14: 123 cc vs 422 cc; p < 0.001), rectum (median V20: 11 % vs 26 %; p < 0.0001), and bladder (median V20: 16 % vs 21 %; p = 0.004). Conclusion: SBPT to the prostate and pelvic lymph nodes is clinically feasible, with low acute toxicity and superior OAR sparing compared to photon-based SBRT. The dosimetric data from this study were used to propose volumetric dose constraints for SBPT planning of the prostate and pelvis. These preliminary results substantiate the rationale for the prospective PROTO-PRIME trial, which will investigate the clinical benefits of SBPT relative to SBRT in this patient population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.